Detectability of EOB-MRI for pancreatic liver metastases after neoadjuvant chemotherapy
Not Applicable
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-jRCT1060220019
- Lead Sponsor
- Fujii Yuki
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 211
Inclusion Criteria
Pancreatic cancer undergoing Neoadjuvant chemotherapy
Resectable and Borderline resectable pancreatic cancer
Exclusion Criteria
Contraindications for contrast enhanced CT or EOB-MRI
Performance status 2,3,4
younger than 20 years old patients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method sensitivity of EOB-MRI for liver metastasis after Neoadjuvant chemotherapy
- Secondary Outcome Measures
Name Time Method specificity, accuracy, positive predictive value,negative predictive value of EOB-MRI for liver metastasis after Neoadjuvant chemotherapy<br>risk factor for liver metastasis after Neoadjuvant chemotherapy